Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

MRI findings in Neurosarcoidosis Patients with Headache as a Primary Presenting Symptom
Headache
P13 - Poster Session 13 (5:30 PM-6:30 PM)
7-008
To determine if there are MRI differences in patients with neurosarcoidosis, who present with headache as a primarily clinical symptom, compared with those who initially present with non-headache symptomatology. To the author’s knowledge, this has not been previously reported in the available literature. 
Neurologic complications occur in approximately 5 to 10 percent of patients with sarcoidosis. Clinical manifestations include cranial nerve palsies, sensory and/or motor deficits, and, commonly, persistent headache. The typical work-up of these patients includes a contrast enhanced brain MRI. 
This is an IRB-approved retrospective chart review  conducted at an urban tertiary care center. 123 patients with Neurosarcoidosis were identified between the years 1980 and 2018 , of whom 110 had a completed MRI at the time of diagnosis. These patients were then separated into two groups. Group A included patients who reported headache as their primary neurological complaint, while group B included patients whose presenting neurological symptom was other than headache. Available brain MRI reports were reviewed for each of these patients. Chi-square test was used for analysis. 
Out of the 110 patients, headache was an initial presenting symptom in 33 patients (Group A), of whom 24, or 73%, had meningeal contrast enhancement on their initial MRI. Of the 77 patients who presented initially with other than headache (Group B), 59, or 77%, did not have meningeal enhancement on their initial MRI (p-value <0.001).
Patients with neurosarcoidosis who present with headache as an initial symptom are more likely to have meningeal contrast enhancement as compared to those who present with other symptomatology. This suggests a clinicoradiologic link between headache and meningeal disruption in patients with neurosarcoidosis.
Authors/Disclosures
Yamin Sallowm, MD (Yamin Sallowm)
PRESENTER 		Dr. Sallowm has nothing to disclose.
Muhammad Affan, MD (University of Minnesota) Dr. Affan has nothing to disclose.
Mirela Cerghet, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Henry Ford Hospital) Dr. Cerghet has nothing to disclose.
Ashhar Ali, DO, FÂ鶹´«Ã½Ó³»­ (Henry Ford Health) Dr. Ali has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Ali has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Ebsco.